NCT02040220View on ClinicalTrials.gov

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)

CompletedOBSERVATIONAL
Enrollment

385

Participants

Timeline

Start Date

January 24, 2014

Primary Completion Date

June 1, 2018

Study Completion Date

November 9, 2018

Conditions
Retinal Vein Occlusion
Interventions
DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

2 mg of Eylea will be treated per one injection at more than one months interval usually.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY